Skip to main content

Table 6 Clinical and immunological parameters and patient survival

From: Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

Parameter

1-year survival rate (%)

Median survival time (days)

P value

Total

58.3

398

 

Age

   

   >=60y

71.4

476

 

   < 60y

50

213

0.4159

Sex

   

   Male

66.7

476

 

   Female

0

282

0.4797

Performance status

   

   0-1

100

834

 

   2

0

112

0.0004

Treatment line

   

   ~2nd

72.9

834

 

   3rd~

42.9

112

0.0629

Reaction at injection site

   

   Strong

75.0

476

 

   Weak

50.9

398

0.5207

CTL

   

   Strong

85.7

-

 

   Weak

33.3

112

0.0176

Regulatory T (%)

   

   High

57.1

476

 

   Low

33.3

282

0.3856

C-reactive protein

   

   >=1.0

25.0

53

 

   < 1.0

71.6

834

0.0284

Hemoglobin

   

   Normal

57.1

834

 

   Low

56.3

398

0.891

Albumin

   

   Normal

57.1

834

 

   Low

62.5

398

0.8256

White blood cell count

   

   High

55.6

-

 

   Normal

66.7

398

0.7070

Neutrophile (%)

   

   High

75.0

834

 

   Low

38.1

282

0.1902

Lymphocyte (%)

   

   High

50.0

282

 

   Low

66.7

398

0.5006